Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P9AC
|
|||
| Former ID |
DAP000578
|
|||
| Drug Name |
Phenelzine
|
|||
| Synonyms |
Fenelzina; Fenelzyna; Fenelzyne; Phenelezine; Phenelzinum; Phenethylhydrazine; Phenylethylhydrazine; Fenelzyna [Polish]; Fenelzyne [Polish]; W1544; Beta-Phenylethylhydrazine; Fenelzina [INN-Spanish]; Nardelzine (TN); Nardil (TN); Phenelzine (BAN); Phenelzine [INN:BAN]; Phenelzinum [INN-Latin]; Phenylethyl hydrazine-HCl; W 1544-A; 1-Hydrazino-2-phenylethane; 2-Phenethylhydrazine; 2-Phenylethylhydrazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z] | Approved | [1], [2], [3] | |
| Skin imperfections [ICD-11: EK71; ICD-10: L91.8] | Patented | [4] | ||
| Therapeutic Class |
Antidepressants
|
|||
| Company |
Parke Davis Div Warner Lambert Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H12N2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CCNN
|
|||
| InChI |
1S/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2
|
|||
| InChIKey |
RMUCZJUITONUFY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 51-71-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9634, 5152742, 8152321, 10524963, 11111653, 11111654, 11335237, 11360476, 11363745, 11364679, 11366307, 11367241, 11368869, 11369803, 11371693, 11372844, 11374089, 11375403, 11377031, 11377966, 11461448, 11466198, 11467318, 11484873, 11485696, 11488825, 11490493, 11492290, 11494665, 15297289, 29222798, 46507348, 47291290, 47365378, 47440429, 47440430, 47515488, 47589153, 47589154, 47662481, 47885575, 48334681, 49698876, 49977970, 50111200, 53787015, 57321933, 74503885, 85789353, 90341694
|
|||
| ChEBI ID |
CHEBI:8060
|
|||
| ADReCS Drug ID | BADD_D01750 ; BADD_D01751 | |||
| SuperDrug ATC ID |
N06AF03
|
|||
| SuperDrug CAS ID |
cas=000051718
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase (MAO) | Target Info | Inhibitor | [4] |
| Monoamine oxidase type B (MAO-B) | Target Info | Inhibitor | [5] | |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7266). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011909. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. | |||
| REF 5 | Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.